H. Lee Moffitt Cancer Center and Research Institute, Inc.

University of South Florida

Dung-Tsa Chen

Mokenge P Malafa

Jennifer Permuth

Johnathan M Lancaster

Douglas C Marchion

Timothy J Yeatman

Domenico Coppola

Steven Alan Enkemann

Amer A Beg

Yoganand Balagurunathan

Jung Wook Choi

Steven Brem

Daniel Jeong

W Douglas Cress

The current invention pertains to miRNAs that are differentially expressed in samples of an individual having pancreatic cancer, or having a high risk of developing pancreatic cancer, as compared to the corresponding sample of an individual not having pancreatic cancer, or having low risk of developing pancreatic cancer, respectively. In certain embodiments, the miRNAs are differentially expressed in a tissue sample or blood plasma sample of an individual having a pancreatic lesion and having a high risk of developing pancreatic cancer as compared to the corresponding tissue sample or blood sample of an individual having the pancreatic lesion and having no risk or low risk of developing pancreatic cancer. These differentially expressed miRNAs can be used as biomarkers for diagnosis, treatment, and/or prevention of pancreatic cancer, particularly, in a subject having a pancreatic lesion. Microarray containing miRNAs indicative of the presence of pancreatic cancer, or having a high risk of pancreatic cancer development, particularly, in a subject having a pancreatic lesion, and methods of use of the microarrays are also provided.

Microrna assay for detection and management of pancreatic cancer precursors

The present invention concerns materials and methods for identifying and classifying pancreatic ductal adenocarcinoma (PDAC) precursors or intraductal papillary mucinous neoplasm (IPMN) using messenger RNAs, microRNAs, long non-coding RNAs, radiomic features, radiologic measures of abdominal/visceral obesity, and combinations thereof, as diagnostic markers for integration with clinical management and interventions for personalized care.

Theranostic tools for management of pancreatic cancer and its precursors

MicroRNA assay for detection and management of pancreatic cancer precursors

Biomarkers, methods, assays, and kits are provided for predicting the efficacy of adjuvant chemotherapy (ACT) in a subject with early-stage non-small cell lung cancer (NSCLC).

Biomarkers and methods for predicting benefit of adjuvant chemotherapy

Despite initial sensitivity BAD-protein phosphorylation were evaluated in patient samples and cell lines as determinants of chemo-sensitivity and/or clinical outcome, and as therapeutic targets. Induced in-vitro OVCA cisplatin-resistance was associated with BAD-pathway expression. Expression of the pathway was also associated with resistance of 7 different cancers cell-types to 8 chemotherapeutic agents. Phosphorylation of the BAD-protein was associated with platinum-resistance in OVCA cells and primary OVCA specimens, and also overall patient survival. Targeted modulation of BAD-phosphorylation levels influenced cisplatin-sensitivity. A 47-gene BAD-pathway signature was associated in-vitro phospho-BAD levels and with survival of 838 patients with ovarian, breast, colon, and brain cancer. The survival advantage associated with both BAD-phosphorylation and also the BAD-pathway signature was independent of surgical cytoreductive status. The BAD apoptosis pathway influences human cancer chemo-sensitivity and overall survival. The pathway is useful as a biomarker of therapeutic response, patient survival, and therapeutic target.

Bad phosphorylation determines ovarian cancer chemo-sensitivity and patient survival

The invention provides for malignancy-risk gene signatures that predict the risk of developing breast cancer, the recurrence of breast cancer, and/or the metastasis of breast cancer. These signatures have numerous clinical applications including assessing risk of breast cancer development following routine breast biopsy, assessing the need for adjuvant radiotherapy after lumpectomy, and determining the need for completion mastectomy following lumpectomy for the breast cancer patient and other treatment plans that are personalized for the patient.

Malignancy-risk signature from histologically normal breast tissue

Methods for predicting NF-kappaB (NF-kB) activity in a tumor, and more particularly to methods for predicting survival and therapeutic outcome, and selecting therapy in subjects with tumors, e.g., adenocarcinomas, e.g., lung adenocarcinomas and melanomas.

Gene signature for the prediction of NF-kappaB activity

The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody against a particular amino acid residue or site. Phospho-specific protein characterization methods include immunohistochemical (IHC), flow cytometric, immunofluorescent, capture-and-detection, or reversed phase assay.

Cancer platinum resistance detection and sensitization method

The present invention relates to biomarkers for neoplasias such as high grade gliomas. The inventors have discovered that the overexpression of senescence associated genes (SAG) is associated with a poor prognosis in subjects with high grade gliomas. The present invention provides SAG biomarkers for predicting response to therapy for subjects having high grade glioma based on dividing the samples into high and low risk groups; diagnosing high grade glioma; monitoring progression of high grade glioma from one biological state to another; and determining efficacy of treatment for high grade gliomas.

Growing community of inventors

Tampa, FL, United States of America

Dung-Tsa Chen